159 related articles for article (PubMed ID: 28224278)
21. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract][Full Text] [Related]
22. The role of neck ultrasound in the follow-up of low- and intermediate- risk papillary thyroid cancer.
de Campos Lopes SG; Dias Silva Ferreira DN; Fernandes VAR; da Costa Cardoso Marques HM; da Silva Santos Pereira RF; Monteiro AMC
Arch Endocrinol Metab; 2022 Sept 08; 66(4):481-488. PubMed ID: 35758832
[TBL] [Abstract][Full Text] [Related]
23. Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.
Tian T; Qi Z; Huang S; Wang H; Huang R
J Clin Endocrinol Metab; 2023 Jul; 108(8):2033-2041. PubMed ID: 36715264
[TBL] [Abstract][Full Text] [Related]
24. Thyroglobulin Antibodies and Tumor Epitope-Specific Cellular Immunity in Papillary Thyroid Cancer.
Allelein S; Ehlers M; Thoma T; Mattes-György K; Antke C; Mamlins E; Muchalla M; Giesel F; Schott M
Horm Metab Res; 2024 Jun; 56(6):424-428. PubMed ID: 38621693
[TBL] [Abstract][Full Text] [Related]
25. The quality of life in papillary thyroid microcarcinoma patients undergoing lobectomy or total thyroidectomy: A cross-sectional study.
Lan Y; Cao L; Song Q; Jin Z; Xiao J; Yan L; Luo Y; Zhang M
Cancer Med; 2021 Mar; 10(6):1989-2002. PubMed ID: 33638269
[TBL] [Abstract][Full Text] [Related]
26. Intermediate-risk thyroid carcinoma: indicators of a poor prognosis.
Faro FN; Bezerra ÂMLB; Scalissi NM; Cury AN; Marone MM; Ferraz C; do Prado Padovani R
Arch Endocrinol Metab; 2021 May; 64(6):764-771. PubMed ID: 34033287
[TBL] [Abstract][Full Text] [Related]
27. Early Dynamic Risk Stratification Decreases Rate of Ablative and Adjuvant Radioiodine Use in ATA Low and Intermediate Risk Papillary Thyroid Cancer Patients.
Gorur SK; Ozbas S; Ilgan S
Sisli Etfal Hastan Tip Bul; 2023; 57(4):451-457. PubMed ID: 38268648
[TBL] [Abstract][Full Text] [Related]
28. Association between surgical extent and recurrence in unilateral intermediate- to high-risk papillary thyroid cancer.
Xu S; Huang H; Dong H; Wang X; Xu Z; Liu S; Liu J
BMC Cancer; 2023 Sep; 23(1):880. PubMed ID: 37723469
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of carbon nanoparticles suspension-guided lymph node dissection during thyroidectomy in patients with thyroid papillary cancer: a prospective, multicenter, randomized, blank-controlled trial.
Zhao J; Wang J; Cheng R; Qin J; Ai Z; Sun H; Guo Z; Zhang X; Zheng X; Gao M
Front Endocrinol (Lausanne); 2023; 14():1251820. PubMed ID: 38260138
[TBL] [Abstract][Full Text] [Related]
30. Comparison of bilateral axillo-breast approach robotic thyroidectomy and open thyroidectomy for papillary thyroid carcinoma.
Zhang R; Chen Y; Deng X; Qiao D; Li X; Yang H
J Robot Surg; 2023 Oct; 17(5):1933-1942. PubMed ID: 37358693
[TBL] [Abstract][Full Text] [Related]
31. Basal or stimulated thyroglobulin in evaluating response to treatment in papillary thyroid carcinoma? A retrospective cohort study.
Barreto L; Ferreira DCG; Corrente JE; Soares CSP; Oliveira CC; Terra SA; Moriguchi SM; Koga KH; Tagliarini JV; da Silva Mazeto GMF
Hormones (Athens); 2024 Mar; 23(1):97-106. PubMed ID: 38015413
[TBL] [Abstract][Full Text] [Related]
32. Extent of thyroid surgery for clinically node-negative papillary thyroid carcinoma with confirmed nodal metastases after prophylactic central neck dissection: a 15-year experience in a single center.
Jo YJ; Choi HR; Park SH; Jeong YJ
Ann Surg Treat Res; 2020 Oct; 99(4):197-204. PubMed ID: 33029478
[TBL] [Abstract][Full Text] [Related]
33. Thyroglobulin as a Rapid and Cost-Effective Biomarker for Diagnosis of Thyroid Carcinoma Brain Metastasis: A Case Report of a Patient with Metastatic Hurthle Cell Thyroid Carcinoma.
Ntotsikas K; Lazarioti S; Daraki V; Drakos E; Tsakalomatis PN; Syntzanaki EK; Moustakis N; Marinis AI; Salapatas-Gkinis A; Xekouki P; Vakis A; Tsitsipanis C
Am J Case Rep; 2023 Oct; 24():e939025. PubMed ID: 37853680
[TBL] [Abstract][Full Text] [Related]
34. Comment on: Lymph node ratio independently associated with postoperative thyroglobulin levels in papillary thyroid cancer.
Xu R
Oral Oncol; 2024 May; 152():106767. PubMed ID: 38579477
[No Abstract] [Full Text] [Related]
35. Surgical and Biochemical Outcomes in Nerve Monitored Reoperation Surgery for Recurrent Papillary Thyroid Carcinoma.
Patel KR; Wang B; Abdelhamid Ahmed AH; Okose OC; Ma H; Behr IJ; Cheung AY; Saito Y; Kamani D; Silver Karcioglu A; Liddy W; Takami H; Cunnane M; Randolph GW
Otolaryngol Head Neck Surg; 2023 Nov; 169(5):1234-1240. PubMed ID: 37245079
[TBL] [Abstract][Full Text] [Related]
36. Combined analysis of circulating epithelial cells and serum thyroglobulin for distinguishing disease status of the patients with papillary thyroid carcinoma.
Lin HC; Liou MJ; Hsu HL; Hsieh JC; Chen YA; Tseng CP; Lin JD
Oncotarget; 2016 Mar; 7(13):17242-53. PubMed ID: 26684026
[TBL] [Abstract][Full Text] [Related]
37. Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer.
Mao Y; Lin R; Wang Y; Yu J
Quant Imaging Med Surg; 2024 May; 14(5):3665-3675. PubMed ID: 38720856
[TBL] [Abstract][Full Text] [Related]
38. Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients.
Chantadisai M; Wongwijitsook J; Ritlumlert N; Rakvongthai Y
Sci Rep; 2024 Feb; 14(1):5001. PubMed ID: 38424177
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of pre-ablative and preoperative thyroglobulin in differentiated thyroid cancer].
Fuenzalida-Mery L; González-Arestizábal T; Portilla-Rojas M; Gac-Espinoza P; Rodríguez-Moreno F; CabanéToledo P; Rappoport-Wurgaft D
Rev Med Chil; 2022 Jul; 150(7):855-860. PubMed ID: 37906818
[TBL] [Abstract][Full Text] [Related]
40. Establishing a Cutoff Serum Thyroglobulin Value for the Diagnosis and Management of Well-Differentiated Thyroid Cancer.
Paudel J
World J Nucl Med; 2023 Sep; 22(3):208-216. PubMed ID: 37854090
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
